Retatrutide

Price range: $180.00 through $245.00

$ USD

$ USD
€ EUR
£ GBP

Retatrutide is an experimental triple agonist medication developed by Eli Lilly designed to activate GLP-1, GIP, and glucagon receptors simultaneously to treat obesity and type 2 diabetes. Phase II trials showed significant weight loss, and Phase III trials are underway to confirm its efficacy and safety for obesity, type 2 diabetes, and non-alcoholic fatty liver disease.

SKU: N/A Category: Uncategorized

What it is:

Retatrutide is a peptide that acts as a triple agonist, meaning it stimulates three types of receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors (GCGR).

Its purpose:

It is being developed for the treatment of obesity and type 2 diabetes mellitus.
It may also help with metabolic dysfunction-associated steatotic liver disease (NAFLD) by reducing liver fat.

How it works:

By activating all three receptors, retatrutide targets weight loss, improves glycemic control, and can offer cardiovascular benefits.

Current status:

It is in Phase III clinical development, following successful Phase II trials.
The Phase II trial results showed significant weight reductions in obese and overweight adults, with an average loss of up to 24.4% at 48 weeks in one study,